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Abstract
Background: Common genetic variation at genes that are imprinted and exclusively maternally
expressed could explain the apparent maternal-specific inheritance of low birthweight reported in
large family pedigrees. We identified ten single nucleotide polymorphisms (SNPs) in H19, and we
genotyped three of these SNPs in families from the contemporary ALSPAC UK birth cohort (1,696
children, 822 mothers and 661 fathers) in order to explore associations with size at birth and cord
blood IGF-II levels.
Results: Both offspring's and mother's H19 2992C>T SNP genotypes showed associations with
offspring birthweight (P = 0.03 to P = 0.003) and mother's genotype was also associated with cord
blood IGF-II levels (P = 0.0003 to P = 0.0001). The offspring genotype association with birthweight
was independent of mother's genotype (P = 0.01 to P = 0.007). However, mother's untransmitted
H19 2992T allele was also associated with larger birthweight (P = 0.04) and higher cord blood IGF-
II levels (P = 0.002), suggesting a direct effect of mother's genotype on placental IGF-II expression
and fetal growth. The association between mother's untransmitted allele and cord blood IGF-II
levels was more apparent in offspring of first pregnancies than subsequent pregnancies (P-
interaction = 0.03). Study of the independent Cambridge birth cohort with available DNA in
mothers (N = 646) provided additional support for mother's H19 2992 genotype associations with
birthweight (P = 0.04) and with mother's glucose levels (P = 0.01) in first pregnancies.
Conclusion: The common H19 2992T allele, in the mother or offspring or both, may confer
reduced fetal growth restraint, as indicated by associations with larger offspring birth size, higher
cord blood IGF-II levels, and lower compensatory early postnatal catch-up weight gain, that are
more evident among mother's smaller first-born infants.
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Background
The maternal-uterine environment has a major influence
on fetal growth and size at birth [1]. Early cross-breeding
experiments in animals demonstrated that fetal growth
could be restrained or enhanced from its genetic poten-
tial, according to the size of the mother [2,3]. In a normal
human birth cohort study, we demonstrated that over
50% of all offspring may have experienced clinically sig-
nificant restraint or enhancement of growth in utero, fol-
lowed by compensatory catch-up or catch-down growth
respectively during the first 2 years of postnatal life [4].
Birth order is an important common determinant of
maternal-uterine restraint, as first-born infants are more
likely to be restrained in utero and show compensatory
postnatal catch-up growth, compared to subsequent-born
infants [5]. Heritable or genetic factors may also contrib-
ute to degree of maternal restraint of fetal growth; from
studies of birthweights in extended human families it has
been suggested that low birthweight may be maternally
transmitted [6]. We previously reported association
between thinness at birth and the common 16189 variant
in mitochondrial DNA, which is maternally transmitted
[7]. Another possible mechanism to explain maternal
inheritance of fetal growth restraint is common variation
in genes that are imprinted and exclusively maternally
expressed.
Many of the genes known to be imprinted and paternally
or maternally expressed influence fetal growth [8]. An
imprinted region on chromosome 11p15.5 in humans
regulates the major fetal growth factor "insulin-like
growth factor-II" (IGF-II). The IGF2 gene is imprinted and
paternally expressed in both the mouse and human fetus
[9,10]. The mechanisms of imprinting and expression of
Igf2 have been thoroughly studied in the mouse. The gene
is regulated by DNA elements close to Igf2, such as silenc-
ers [11] and activators [12], and particularly by enhancers
located distal to the neighbouring maternally expressed
gene H19 [13,14]. Access to these enhancers is restricted
by an epigenetically controlled insulator upstream of H19
[15-18]. Finally, the maternally expressed H19 gene itself
does not code for a protein, but the RNA has growth sup-
pressing functions [19], potentially through inhibiting
translation of IGF2 RNA [20].
We therefore aimed to demonstrate whether common
genetic variation in human H19 may be associated with
fetal growth restraint in a large representative birth cohort.
We identified a common H19 2992 C>T SNP that was
associated with offspring birth size, cord blood IGF-II lev-
els, and infancy catch-up weight gain. These associations
were more evident among first-born infants, and we pro-
pose that the common H19  2992T allele may confer
reduced fetal growth restraint.
Results
Of the ten SNPs that we identified in the H19 region, we
selected three SNPs (2992 C/T; 1737 A/G; and 3238 A/G)
that marked different common H19 haplotypes for geno-
typing in ALSPAC offspring DNA samples for genetic asso-
ciation studies.
Associations with offspring H19 genotypes
Offspring H19 2992 SNP genotypes showed significant
associations with size at birth (Table 1). However, neither
H19 1737 nor 3231 genotypes were associated with birth
size (data not shown).
H19 2992, 1737 and 3231 genotypes were in significant
linkage disequilibrium, and haplotype analysis revealed
only 7 genotype combinations with frequency >1%. Only
those two haplotypes that included a 2992T allele had
birthweights that were above the average [see Additional
file 1].
Table 1: Birth size and cord IGF-II levels by offspring H19 2992 genotype (ALSPAC cohort)
CC CT TT PA PD
(n = 1075) (n = 518) (n = 54)
Weight (gm) 3468 ± 488 3522 ± 486 3524 ± 587 0.03 0.02
Length (cm) 50.7 ± 2.0 50.9 ± 2.0 50.9 ± 2.1 0.08 0.06
Head circ. (cm) 34.9 ± 1.2 34.9 ± 1.3 35.0 ± 1.6 0.3 0.4
(n = 226) (n = 110) (n = 13)
Cord IGF-II (ng/dl) 275 ± 78 277 ± 79 337 ± 91 0.1 0.3
Mean ± SD, adjusted for sex, gestation and parity.
PA = P value for additive genetic model (per T allele)
PD = P value for dominant genetic model (CC versus T/*)BMC Genetics 2005, 6:22 http://www.biomedcentral.com/1471-2156/6/22
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Associations with mother's H19 2992 genotype
The H19 2992 SNP was subsequently genotyped in DNA
samples collected from mothers and fathers, for which the
family relationships had been validated by genotyping.
H19  2992 genotype in mothers, but not in fathers,
showed associations with size at birth, and also with cord
blood IGF-II levels (Table 2). Mother's H19 2992 geno-
type associations were independent of mother's pre-preg-
nancy weight and height (additive models: birthweight: P
= 0.001; cord IGF-II levels: P = 0.0005). The association
between mother's H19 2992 genotype and IGF-II levels
appeared to vary with mother's parity (birth order), being
evident only in first pregnancies (Figure 1), although for-
mal test for interaction did not reach significance (P =
0.06). When both mother's and offspring's genotypes
were included in a multivariate analysis, birthweight was
significantly associated with both mother's H19 2992 gen-
otype (P < 0.05) and also offspring's H19 2992 genotype
(P = 0.01), suggesting that there were separate effects of
mother's and offspring's genotype on birthweight.
Mother's untransmitted H19 2992 allele effects
Effects of mother's genotype, independent of transmis-
sion to the offspring, were examined by looking at associ-
ation with mother's H19 2992 CC versus CT genotype
within CC genotype offspring. Mother's untransmitted T
versus C allele was associated with larger birthweight (P =
0.04) and higher cord blood IGF-II levels (P = 0.002;
Table 3). As suggested by the overall associations with
mother's genotype (in Figure 1), the effect of mother's
untransmitted allele on IGF-II levels was clearer in first
pregnancies (P = 0.0002) than in subsequent pregnancies
(P = 0.36; P-interaction between mother's untransmitted
allele and birth order = 0.03).
Those results indicate that the H19 2992 SNP associations
may depend on mother's genotype. However, offspring
H19 2992 SNP associations were also seen independent
of mother's genotype; among CC genotype mothers, off-
spring CC vs. CT genotype was also associated with birth-
weight (P = 0.007, Table 4).
H19 2992 allele transmission and parent-of-origin effects
Among the validated parent-offspring trios, comparison
of allele transmission from heterozygous parents to their
offspring showed that T versus C allele transmission was
not associated with birthweight (P = 0.22, number of
observations = 204), nor with cord blood IGF-II levels (P
= 0.52, number of observations = 38). Nor was there any
difference between paternal and maternal T allele trans-
mission (parent-of-origin effects) on birthweight (P =
0.92, number of observations = 87), or on IGF-II levels (P
= 0.81, number of observations = 15). Data on mother's
parents' genotypes were unavailable.
Genotype associations with postnatal weight gain
1,449 ALSPAC children were followed-up to age 3 years.
Neither offspring nor parental H19  genotypes showed
association with offspring body size at age 3 years (not
shown). The apparent loss of T allele-related size advan-
tage between birth and age 3 years was explained by
Table 2: Birth size by mothers or fathers H19 2992 genotype (ALSPAC cohort)
Mothers genotype CC CT TT PA PD
(n = 550) (n = 242) (n = 30)
Weight (gm) 3457 ± 474 3543 ± 508 3595 ± 485 0.003 0.003
Length (cm) 50.7 ± 2.0 51.0 ± 1.9 51.1 ± 1.8 0.04 0.04
Head circ. (cm) 34.8 ± 1.2 35.1 ± 1.3 34.9 ± 1.4 0.07 0.03
(n = 164) (n = 61) (n = 9)
Cord IGF-II (ng/dl) 266 ± 72 312 ± 99 312 ± 92 0.0003 0.0001
Fathers genotype CC CT TT PA PD
(n = 442) (n = 201) (n = 18)
Weight (gm) 3492 ± 491 3474 ± 472 3537 ± 519 0.9 0.7
Length (cm) 50.8 ± 1.9 50.8 ± 1.9 51.1 ± 1.7 0.8 0.9
Head circ. (cm) 34.9 ± 1.2 34.9 ± 1.2 35.0 ± 1.2 0.9 0.7
(n = 76) (n = 37) (n = 3)
Cord IGF-II (ng/dl) 270 ± 75 290 ± 93 245 ± 96 0.5 1.0
Mean ± SD, adjusted for sex, gestation and parity.
PA = P value for additive genetic model (per T allele)
PD = P value for dominant genetic model (CC versus T/*)BMC Genetics 2005, 6:22 http://www.biomedcentral.com/1471-2156/6/22
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Birthweight SD score (A) and cord blood IGF-II levels at birth (B) in the ALSPAC cohort, by mother's H19 2992 genotype, and  stratified by birth order ("Primip" = mother's first child; "Non-primip" = second or subsequent child) Figure 1
Birthweight SD score (A) and cord blood IGF-II levels at birth (B) in the ALSPAC cohort, by mother's H19 2992 genotype, and 
stratified by birth order ("Primip" = mother's first child; "Non-primip" = second or subsequent child). Mean ± 95% CI. First-
born infants had lower birthweights than infants of subsequent pregnancies (Ref. 5). Associations with mother's genotype (CC 
vs. T* [CT or TT]) were only seen in first pregnancies.BMC Genetics 2005, 6:22 http://www.biomedcentral.com/1471-2156/6/22
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slower rates of weight gain during this period (Table 5). As
with birthweight and IGF-II levels, the H19 2992 geno-
type associations with postnatal weight gain were more
apparent in offspring of first pregnancies (Figure 2).
Replication of mother's H19 2992 genotype associations in 
the Cambridge cohort
In the independent Cambridge birth cohort (n = 646
births analysed), we obtained additional support for the
association between mother's H19 2992T allele and larger
birthweight in offspring of first pregnancies (P = 0.04, Fig-
ure 3A). Mother's glucose levels one hour post oral glu-
cose at 27 to 32 weeks gestation (mean ± SD: 5.5 ± 1.2
mmol/l) were positively related to offspring birthweight
(r = 0.14, P = 0.01), and mother's H19 2992 T/* genotype
was also associated with higher mother's glucose levels
during first pregnancies (P = 0.01, Figure 3B).
Discussion
In two separate contemporary birth cohorts we have iden-
tified associations between a common H19  2992
genotype and birthweight. This SNP is located in H19
exon 5 [see Additional file 2], however its effect on mRNA
structure or function is unknown and H19 has no protein
product. An insulator upstream of H19  [15-18] and
enhancers downstream [13,14] regulate imprinting of
IGF2, which encodes a major fetal growth factor [21]. In
addition H19 RNA may suppress IGF2 expression in trans
[20] and has tumour suppressor functions in cell transfec-
tion studies [19]. Consistent with the birthweight
Table 3: Birthweight and IGF-II levels by maternal H19 2992 genotype, within CC genotype offspring (i.e. effect of mother's 
untransmitted allele), (ALSPAC cohort)
Mother's Genotype ANOVA
CC CT
Birthweight (gm) 3431 ± 474 3533 ± 505 P = 0.04
(n = 407) (n = 96)
Cord IGF-II (ng/dl) 264 ± 72 320 ± 108 P = 0.002
(n = 124) (n = 22)
Mean ± SD, adjusted for sex, gestation and parity.
Table 4: Birthweight and IGF-II levels by offspring H19 2992 genotype, within CC genotype mother's (i.e. effect of fetal genotype), 
(ALSPAC cohort)
Offspring Genotype ANOVA
CC CT
Birthweight (gm) 3425 ± 490 3535 ± 495 P = 0.007
(n = 408) (n = 126)
Cord IGF-II (ng/dl) 262 ± 80 266 ± 98 P = 0.8
(n = 125) (n = 36)
Mean ± SD, adjusted for sex, gestation and parity.
Table 5: Size at 3 years, and growth from birth, by offspring H19 2992 genotype, (ALSPAC cohort)
Offspring genotype CC CT TT PA PD
(n = 946) (n = 462) (n = 41)
Weight at 3 y (kg) 15.0 ± 1.7 14.9 ± 1.7 14.8 ± 1.7 0.4 0.4
Height at 3 y (cm) 95.6 ± 3.6 95.3 ± 3.5 95.2 ± 3.7 0.2 0.2
Change in Weight SDS 0–3 y 0.01 ± 1.17 -0.13 ± 1.07 -0.10 ± 1.29 0.01 0.02
Change in Height SDS 0–3 y 0.06 ± 1.12 -0.10 ± 1.02 -0.17 ± 1.26 0.01 0.01
Mean ± SD, adjusted for sex and age
PA = P value for additive genetic model (per T allele)
PD = P value for dominant genetic model (CC versus T/*)BMC Genetics 2005, 6:22 http://www.biomedcentral.com/1471-2156/6/22
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Postnatal weight gain (change in weight SD score 0–3 years) in the ALSPAC cohort, by offspring's (A) or mother's (B) H19  2992 genotype, and stratified by birth order ("Primip" = mother's first child; "Non-primip" = second or subsequent child) Figure 2
Postnatal weight gain (change in weight SD score 0–3 years) in the ALSPAC cohort, by offspring's (A) or mother's (B) H19 
2992 genotype, and stratified by birth order ("Primip" = mother's first child; "Non-primip" = second or subsequent child). Mean 
± 95% CI. The overall association between weight gain and offspring genotype (CC vs. T* [CT or TT], P = 0.01; Table 5) was 
only apparent in first-born offspring.BMC Genetics 2005, 6:22 http://www.biomedcentral.com/1471-2156/6/22
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Birthweight SD score (A) and mother's glucose levels one hour post-oral glucose load at 27 to 32 weeks gestation (B) in the  Cambridge cohort, by mother's H19 2992 genotype, and stratified by birth order ("Primip" = mother's first child; "Non-primip"  = second or subsequent child) Figure 3
Birthweight SD score (A) and mother's glucose levels one hour post-oral glucose load at 27 to 32 weeks gestation (B) in the 
Cambridge cohort, by mother's H19 2992 genotype, and stratified by birth order ("Primip" = mother's first child; "Non-primip" 
= second or subsequent child). Mean ± 95% CI. Associations with mother's genotype (CC vs. T* [CT or TT]) were only seen 
in first pregnancies.BMC Genetics 2005, 6:22 http://www.biomedcentral.com/1471-2156/6/22
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association, H19 2992 genotype was also associated with
cord blood IGF-II protein levels at birth.
Birthweight associations were found with both mother's
and offspring's H19 2992 genotypes, and it is not clear
whether our findings represent direct effects of mother's
genotype, offspring genotype, or both. As in other popu-
lation studies, the low number of available DNA samples
and genotypes from fathers contributed to relatively lower
statistical power to formally detect effects of H19 2992
allele transmission. However, we did observe significant
birthweight and cord blood IGF-II associations with
mother's untransmitted allele, suggesting direct effects of
mother's genotype. While in mice H19 and IGF2 are not
expressed postnatally [22], in humans IGF2 expression
continues into adulthood [23]. In most adult tissues IGF2
expression remains monoallelic as in the fetus, however
biallelic expression is observed in adult human liver [23].
It is possible that mother's H19 2992 genotype may regu-
late IGF2 expression in maternally-derived placental tis-
sues. Alternatively, H19  regulation of maternal IGF2
expression could influence mother's glucose metabolism
[24] and thereby influence placental glucose transfer and
fetal growth [25]. Offspring H19 2992 genotype was asso-
ciated with birthweight, but not with IGF-II levels. It is
possible that this discrepancy could relate to reduced
power due to the smaller number of IGF-II samples avail-
able, or alternatively it could be possibly explained by a
non-IGF-II mediated effect of H19 on birthweight. The
association between birthweight and IGF-II levels in cord
blood at birth is weak, and it is possible that the effects of
IGF-II on fetal growth may be specific to certain tissues or
developmental stages in fetal life [26].
The  H19  2992 genotype associations with birthweight
and IGF-II were independent of mother's body size and
were more apparent in mother's first pregnancies. First-
born offspring are more growth-restrained in utero than
subsequent children, as evident by smaller birth size and
compensatory rapid postnatal weight gain within the first
2 to 3 years [5]. The mechanism of growth restraint seen
in first pregnancies is unknown, but could reflect a
maternally inherited genetic trait with subsequent relaxa-
tion of restraint in later pregnancies [27]. We propose that
the common H19 2992T allele, either in the mother or
offspring, confers reduced fetal growth restraint particu-
larly among first-born infants as indicated by larger birth
size and less postnatal compensatory catch-up weight
gain.
In subsequent pregnancies and in larger babies, a mende-
lian pattern of inheritance of birthweight is observed [27].
It was in these second and subsequent pregnancies that we
saw association between size at birth and common allele
class at the insulin gene minisatellite (INS VNTR) [28],
which also regulates IGF2 expression [29]. Offspring INS
VNTR class III alleles were associated with larger head size
and higher IGF-II levels at birth, and this effect was
masked in growth-restricted first pregnancies [28]. Thus,
there may be important interaction between maternal par-
ity and imprinted and non-imprinted genes involved in
the regulation of IGF-II expression and fetal growth.
Altogether we identified ten SNPs in H19. Given that there
is no confirmed function for the H19 transcript in vivo
[30], it is difficult to assess the effect of the H19 2992 SNP.
It is possible that this variant: (a) may alter the RNA itself,
and might influence the putative growth suppressing
function of the H19 RNA; (b) may influence levels of H19
transcripts, leading to an effect as above; (c) may be in
linkage with an unidentified regulatory element in H19
acting on IGF2 in cis; (d) may be in linkage with variants
in known cis regulatory elements for IGF2, such as the
insulator or the enhancers. Further work, including sys-
tematic genotyping of other SNPs in the extended region
and functional studies, will be required to identify the
causal variant(s) and, hence, possible mechanisms by
which they may influence birthweight and cord blood
IGF-II levels. The identification of separate effects of H19
on fetal growth, by acting both within the mother and
also within the fetus, could be confirmed by studying a
larger population to provide greater power to detect an
interaction between mother's and offspring's genotypes,
and by exploration of grand-parental genotype and allele
transmission to the mother. Intriguingly, while we con-
firmed that the offspring 2992 genotype (CC vs. CT) asso-
ciation with birthweight was independent of mother's
genotype (within CC mothers; Table 4), that finding also
raises the surprising suggestion of a paternal H19 allele
transmission effect, however, we did not detect any formal
association with paternal transmission. An alternative
explanation would be that the H19 2992 is in LD with
another paternally transmitted determinant of birth-
weight. Further studies with larger numbers of complete
informative trios will be needed to clarify this issue.
Conclusion
In conclusion, the common H19  2992T allele, in the
mother or offspring or both, may confer reduced fetal
growth restraint, as indicated by associations with larger
offspring birth size, higher cord blood IGF-II levels, and
lower compensatory early postnatal catch-up weight gain.
These observations may have implications for the early
origins of adult disease hypothesis [31]. Following the
original observations of association between small size at
birth and increased later risks for cardiovascular disease
and diabetes [32], recent studies have highlighted that
these risks are strongest in subjects with the combination
of fetal growth restraint followed by rapid postnatal catch-
up growth [33]. Common factors that lead to fetal growthBMC Genetics 2005, 6:22 http://www.biomedcentral.com/1471-2156/6/22
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restraint in humans include mother's smoking and 1st
pregnancies [5]. Common variants in exclusively mater-
nally-expressed genes (such as H19) or maternally trans-
mitted genes (such as in mitochondrial DNA) [7] could
also contribute to fetal growth restraint and compensatory
postnatal catch-up growth.
Methods
Subjects
The Avon Longitudinal Study of Parents and Children
(ALSPAC) birth cohort numbers 14,185 children com-
prising over 80% of all births in three Bristol based health
authorities between April 1991 and December 1992 [34].
Our studies are confined to a 10% sub-cohort ("Children
in Focus") [4] and a second (control) cohort for which
there were detailed data on size at birth and subsequent
childhood growth. In these families, offspring DNA was
extracted from cord blood samples collected at birth,
mothers DNA from venous blood samples in pregnancy,
and fathers DNA from mouthswab samples. H19 geno-
types were analysed in available DNA samples from 1,696
children, 822 mothers and 661 fathers. Cord blood sam-
ples were collected at birth in 338 of these infants and
assayed for IGF-II levels as previously reported [26]; these
infants had larger birthweight (mean = 3546 g) than
infants for whom cord blood was unavailable (3467 g),
but were no different in H19 +2992 genotype (chi-square:
P = 0.7)
The Cambridge (Wellbeing) birth cohort was studied to
provide independent confirmation of mother's H19 gen-
otype associations. This cohort was recruited from full-
term, singleton deliveries at the Rosie Maternity Unit,
Cambridge, 1999 to 2000. Routinely collected clinical
data were available on offspring birthweight and mother's
whole blood glucose levels measured at one hour follow-
ing a standard dose oral glucose load at 27 to 32 weeks of
gestation. Mother's were selected of full-term, singleton
infants. Exclusion criteria were mother's hypertension and
treatment for diabetes during pregnancy. We sought per-
mission from the mother's General Practitioner to
approach the mother to collect her DNA sample by postal
mouthswab kits and questionnaire data on her other chil-
dren. Mother's DNA was extracted and genotyped for the
H19  2992 genotype only. Local ethical committee
approval and signed informed consent from mothers were
obtained.
SNP identification
In an independent cohort of 20 subjects, ten SNPs were
identified in the H19 region using denaturing high per-
formance liquid chromatography (Wave™) and were char-
acterised by sequencing of PCR products (SNPs submitted
to dbSNP). Confirmation and assessment of allele fre-
quency was obtained by genotyping a second independ-
ent cohort of 100–200 subjects. We selected three H19
SNPs as these SNPs marked different haplotypes (2992 C/
T [rs217727], 1737 A/G [rs2067051], and 3238 A/G
[rs2839703]; the SNP numbers relate to their position in
accession number M32053). We genotyped these three
SNPs in offspring DNA samples from the ALSPAC cohort
for genetic association studies. The H19 2992 SNP was
subsequently genotyped in DNA samples from ALSPAC
parents, and from mothers in the Cambridge cohort.
H19 2992 C/T genotyping
Genomic DNA (40 ng) was amplified in a reaction mix-
ture containing 1x ammonium reaction buffer, 50 µM
each dNTP, 500 µM magnesium, 225 ng each primer (for-
ward: 5'-aaagacaccatcggaacagc-3', reverse: 5'-agcttccagact
aggcgagg-3'), 10% (v/v) dimethylsulphoxide and 0.6
units DNA polymerase (Bioline, London, UK) in a 45 µL
reaction volume. After an initial 5 min. incubation at
94°C, twenty amplification cycles of 94°C (65 sec.), 58°C
(65 sec., dropping 0.5°C per cycle) and 72°C (140 sec.)
were performed. This was followed by 14 cycles of 94°C
(65 sec.), 48°C (65 sec.) and 72°C (140 sec.) and a final
incubation of 72°C for 10 min. After overnight digestion
with Fnu4HI (2 units per reaction; New England Biolabs,
Hitchin, UK) at 37°C, PCR products were separated by
agarose gel electrophoresis. This gave a 351 bp band for
the 'T' allele and a 304 bp band for the 'C' allele. The
observed genotype frequencies: CC: 65.3%, CT: 31.5%,
TT: 3.3% (Table 1) were in Hardy Weinberg equilibrium
(chi-square test: P = 0.99). The H19 2992 SNP was also
genotyped in the parents DNA samples.
H19 1737 A/G genotyping
The reaction mix for the H19 1737 genotyping was the
same as for the 2992 SNP, with the exception of the oligo-
nucleotide primer sequences (forward: 5'-aaggtgacatct-
tctcgggg-3'; reverse: 5'-tgagagctcattcactccgc-3'). The
amplification conditions were the same as those for the
2992 SNP except that the annealing temperatures were
4°C higher throughout. Overnight digestion with Tsp45I
(2 units per reaction; New England Biolabs) produced
474 and 131 bp bands for the 'A' allele and 329, 145 and
131 bp fragments for the 'G' allele. The observed genotype
frequencies (AA: 23.1%, AG: 52.6%, GG: 24.4%) were in
Hardy Weinberg equilibrium (chi-square test: P = 0.5).
H19 3238 A/G genotyping
The reaction mix for the H19 3238 genotyping was the
same as for the 2992 SNP, with the exception of the oligo-
nucleotide primer sequences (forward: 5'-aaagacaccatcg-
gaacagc-3'; reverse: 5'-agcttccagactaggcgagg-3').
Amplification conditions were the same as those for the
2992 SNP except that the annealing temperatures were
4°C higher throughout. Overnight digestion with DdeI (2
units per reaction; New England Biolabs) produced 137BMC Genetics 2005, 6:22 http://www.biomedcentral.com/1471-2156/6/22
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and 44 bp bands and multiple small bands (116, 76, 60
and 26 bp) for the 'A' allele and a 181 bp band along with
the same multiple small bands for the 'G' allele. The
observed genotype frequencies (AA: 38.0%, AG: 48.5%,
GG: 13.5%) were in Hardy Weinberg equilibrium (chi-
square test: P = 0.8).
Microsatellite validation of parental DNA samples
Parental DNA samples were validated using amplification
of markers D16S539, D7S820, D13S317 and D5S818
(Geneprint Multiplex-GammaSTR kit, Promega, South-
ampton, UK) on an ABI 3700 instrument as previously
described [28]. We had DNA samples from 597 complete
and validated parent-offspring trios.
Calculations and statistics
Postnatal weight and length gains were calculated by
transforming weight and length data into SD scores allow-
ing for variation relating to (gestational) age and gender,
using the formula [SD score = individual value – group
mean / group SD] [35], and then calculating changes in
weight and length SD score between birth to 3 years.
Associations between offspring or mother's genotype and
size at birth were determined by ANOVA. Multivariate
analysis (general linear models) was used to identify
independent effects of mother's and offspring genotypes.
Associations with H19  2992 allele transmission were
assessed by TDT using both quantitative and qualitative
methods. Parent-of-origin effects were sought using quan-
titative and qualitative methods, allowing for possible
confounding by the effects of non-transmission of
mother's alleles [36,37].
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